Advertisement

Cellectis bioresearch Inc., the Cambridge-based subsidiary of Cellectis Group in Paris, has received a five-year contract worth up to $9.5 million from the National Institutes of Health (NIH) to develop stem cell technologies.

Advertisement
Advertisement